Trimethyl chitosan-cysteine nanoparticles for systemic delivery of tnf-α sirna via oral and intraperitoneal routes

Pharmaceutical Research

Volumn 30, Issue 10, 2013, Pages 2596-2606

  He, Chunbai ^a   Yin, Lichen ^a   Tang, Cui ^a   Yin, Chunhua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

administration route; gene delivery; molecular weight; polymeric nanoparticles; TNF siRNA

Indexed keywords

NANOPARTICLE; SMALL INTERFERING RNA; TRIMETHYL CHITOSAN CYSTEINE NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; MALE; MOLECULAR STABILITY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERITONEUM MACROPHAGE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; CHITOSAN; CYSTEINE; DRUG CARRIERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INJECTIONS, INTRAPERITONEAL; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; NANOPARTICLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883870702     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1086-4     Document Type: Article

References (33)

1. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711-9.
2. Cho H, Chong S, Chung S, Shim C, Kim D. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment. Pharm Res. 2012;29(4):1007-19.
3. Tiemann K, Rossi JJ. RNAi-based therapeutics: current status, challenges and prospects. EMBO Mol Med. 2009;1(3):142-51.
4. Jensen LB, Griger J, Naeye B, Varkouhi AK, Raemdonck K, Schiffelers R, et al. Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression. Pharm Res. 2012;29(3):669-82.
5. Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release. 2012;161(2):554-65.
6. Tesz GJ, Aouadi M, Prot M, Nicoloro SM, Boutet E, Amano SU, et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J. 2011;436:351-62.
7. Troiber C, Wagner E. Nucleic acid carriers based on precise polymer conjugates. Bioconjug Chem. 2011;22(9):1737-52.
8. Pelet JM, Putnam D. A combinatorial library of bi-functional polymeric vectors for siRNA delivery in vitro. Pharm Res. 2013;30(2):362-76.
9. Kwok A, Hart SL. Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. Nanomedicine. 2011;7(2):210-9.
10. Schafer J, Hobel S, Bakowsky U, Aigner A. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010;31(26):6892-900.
11. Brissault B, Leborgne C, Scherman D, Guis C, Kchler A. Synthesis of poly(propylene glycol)-block-polyethylenimine triblock copolymers for the delivery of nucleic acids. Macromol Biosci. 2011;11(5):652-61.
12. Howard KA. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev. 2009;61(9):710-20.
13. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115(2):216-25.
14. Zhao X, Yin LC, Ding JY, Tang C, Gu SH, Yin CH, et al. Thiolated trimethyl chitosan nanocomplexes as gene carriers with high in vitro and in vivo transfection efficiency. J Control Release. 2010;144(1):46-54.
15. Marschütz MK, Bernkop-Schnürch A. Thiolated conjugates: self-crosslinking properties of thiolated 450 kDa poly(acrylic acid) and their influence on mucoadhesion. Eur J Pharm Sci. 2002;15(4):387-94.
16. Liu WG, Zhang X, Sun SJ, Sun GJ, Yao KD. N-alkylated chitosan as a potential nonviral vector for gene transfection. Bioconjug Chem. 2003;14(4):782-9.
17. Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed Microdevices. 2008;10(2):321-8.
18. Yin LC, Ding JY, He CB, Cui LM, Tang C, Yin CH. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials. 2009;30(29):5691-700.
19. Aouadi M, Tesz GJ, Nicoloro SM, Wang MX, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009;458(7242):1180-4.
20. Zhang J, He CB, Tang C, Yin CH. Ternary polymeric nanoparticles for oral siRNA delivery. Pharm Res. 2013;30(5):1228-39.
21. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharmaceut. 2009;6(3):686-95.
22. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater. 2012;11(4):316-22.
23. Imam ME, Hornof M, Valenta C, Reznicek G, Bernkop-Schnürch A. Evidence for the interpenetration of mucoadhesive polymers into the mucus gel layer. STP Pharm Sci. 2003;13(3):171-6.
24. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine- mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7(5):657-63.
25. Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006;58(1):32-45.
26. Shim MS, Kwon YJ. Controlled cytoplasmic and nuclear localization of plasmid DNA and siRNA by differentially tailored polyethylenimine. J Control Release. 2009;133(3):206-13.
27. Mohanan D, Slutter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147(3):342-9.
28. Cherif MS, Shuaibu MN, Kurosaki T, Helegbe GK, Kikuchi M, Yanagi T, et al. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine. 2011;29(48):9038-50.
29. Chertok B, David AE, Yang VC. Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release. 2011;155(3):393-9.
30. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 2009;17(1):162-8.
31. O'Neill MJ, Bourre L, Melgar S, O'Driscoll CM. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov Today. 2011;16(5-6):203-18.
32. Akhtar S. Oral delivery of siRNA and antisense oligonucleotides. J Drug Target. 2009;17(7):491-5.
33. Wei W, Wang LY, Yuan L, Yang XD, Su ZG, Ma GH. Bioprocess of uniform-sized crosslinked chitosan microspheres in rats following oral administration. Eur J Pharm Biopharm. 2008;69(3):878-86.